Chimeric Antigen Receptor T-Cell Therapy Market Research, Analysis and Forecast to 2033

According to Future Market Insights, the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market demand is expected to grow at a 6.9% CAGR from 2023 to 2033. The global market for Chimeric antigen receptor (CAR) T-Cell Therapy is expected to reach US$ 6.82 billion by 2033. One of the primary benefits of CAR T-Cell Therapy is its high efficacy rates. CAR T-Cell Therapy has showed up to 90% response rates in clinical trials in some types of leukaemia and lymphoma. This represents a significant advancement above conventional cancer treatments, which normally have response rates of 20-30%.

The prospect of long-term remissions is another advantage of CAR T-Cell Therapy. In certain cases, CAR T-Cell Therapy has resulted in total remission, which implies that there is no evidence of cancer in the body. This is especially hopeful for people who have relapsed or refractory cancer and have exhausted all other treatment options.

As additional clinical trials are completed and drugs are licenced, the market for CAR T-Cell Therapy is expected to grow in the future years. In addition to the two currently approved drugs, several more CAR T-Cell Therapy treatments for different cancers are in late-stage clinical trials. Advances in gene editing technology are also expected to enhance the industry, enabling for the development of more effective CAR T-cell therapies with fewer side effects.

Competitive Landscape

Key players in the Chimeric antigen receptor (CAR) T-Cell Therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC and Pfizer Inc.

Read More Details@ https://www.futuremarketinsights.com/reports/chimeric-antigen-receptor-t-cell-therapy-market

Key Segments Profiled in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Survey

By Type:

  • Abecma
  • Breyanzi
  • Kymriah
  • Tecartus
  • Yescarta
  • Others

By Application:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Autoimmune Disorders
  • Other Application

By End User:

  • Hospitals
  • Cancer Care Treatment Centers

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more